We are live on
!
Find out more
GCP
GSA Capital Partners Portfolio holdings
AUM
$1.59B
1-Year Est. Return
39.81%
This Fund
S&P 500
This Quarter
Est. Return
+5.65%
1 Year Est. Return
+39.81%
3 Year Est. Return
+94.75%
5 Year Est. Return
+73.44%
10 Year Est. Return
+404.29%
AUM
$1.01B
AUM Growth
+$205M
(+25%)
Cap. Flow
+$234M
Cap. Flow
% of AUM
23.15%
Top 10 Holdings %
Top 10 Hldgs %
4.25%
Holding
2,085
New
689
Increased
399
Reduced
339
Closed
654
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
National Vision
EYE
|
+$5.45M |
| 2 |
Altimmune
ALT
|
+$4.45M |
| 3 |
FRC
First Republic Bank
FRC
|
+$4.06M |
| 4 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$3.99M |
| 5 |
Hilton Worldwide
HLT
|
+$3.96M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PG&E
PCG
|
+$7.74M |
| 2 |
Dropbox
DBX
|
+$3.02M |
| 3 |
Progressive
PGR
|
+$2.77M |
| 4 |
Southwest Airlines
LUV
|
+$2.69M |
| 5 |
Transocean
RIG
|
+$2.59M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 15.8% |
| 2 | Consumer Discretionary | 14.87% |
| 3 | Healthcare | 14.13% |
| 4 | Financials | 11.49% |
| 5 | Industrials | 11.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ITOS
1276
DELISTED
iTeos Therapeutics
ITOS
| $180K | 0.02% |
+13,251
| New | +$237K |
|
|
ESPR
1277
DELISTED
Esperion Therapeutics
ESPR
| $179K | 0.02% |
112,584
+94,367
| +518% | +$487K |
|
1278
Sierra Bancorp
BSRR
$525M
| $178K | 0.02% |
+10,343
| New | +$208K |
|
1279
Barings BDC
BBDC
$965M
| $177K | 0.02% |
+22,333
| New | +$187K |
|
1280
Viavi Solutions
VIAV
$9.66B
| $177K | 0.02% |
+16,336
| New | +$178K |
|
|
OPRA
1281
Opera Ltd
OPRA
$1.79B
| $176K | 0.02% |
+17,349
| New | +$134K |
|
1282
Tronox
TROX
$1.04B
| $176K | 0.02% |
12,237
-31,069
| -72% | -$479K |
|
|
AGS
1283
DELISTED
PlayAGS
AGS
| $175K | 0.02% |
24,445
-4,027
| -14% | -$25.1K |
|
1284
Greenwich LifeSciences
GLSI
$211M
| $175K | 0.02% |
12,658
-120
| -0.9% | -$1.9K |
|
|
EIGR
1285
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $175K | 0.02% |
6,517
+3,916
| +151% | +$182K |
|
|
FSR
1286
DELISTED
Fisker Inc.
FSR
| $173K | 0.02% |
+28,182
| New | +$194K |
|
1287
Kodiak Sciences
KOD
$2.84B
| $170K | 0.02% |
27,397
-120,740
| -82% | -$845K |
|
1288
Lexicon Pharmaceuticals
LXRX
$1.1B
| $170K | 0.02% |
+69,791
| New | +$160K |
|
|
BRDG
1289
DELISTED
Bridge Investment Group
BRDG
| $166K | 0.02% |
+14,655
| New | +$198K |
|
|
COMS
1290
DELISTED
COMSovereign Holding Corp. Common Stock
COMS
| $166K | 0.02% |
+77,220
| New | +$368K |
|
1291
CarParts.com
PRTS
$54.7M
| $165K | 0.02% |
3,083
+452
| +17% | +$28.6K |
|
|
PSTX
1292
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $164K | 0.02% |
53,399
-42,070
| -44% | -$252K |
|
1293
Mayville Engineering Co
MEC
$617M
| $163K | 0.02% |
10,949
-18,331
| -63% | -$267K |
|
1294
Plug Power
PLUG
$3.04B
| $163K | 0.02% |
13,918
-31,661
| -69% | -$453K |
|
1295
Douglas Elliman
DOUG
$162M
| $161K | 0.02% |
54,384
-134,918
| -71% | -$538K |
|
|
SURF
1296
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $161K | 0.02% |
230,292
-46,111
| -17% | -$37.4K |
|
|
OCFT
1297
DELISTED
OneConnect Financial Technology
OCFT
| $160K | 0.02% |
30,068
+15,045
| +100% | +$101K |
|
1298
VistaGen Therapeutics
VTGN
$12.8M
| $159K | 0.02% |
42,507
-127,338
| -75% | -$668K |
|
|
NAGE
1299
Niagen Bioscience
NAGE
$247M
| $159K | 0.02% |
103,742
+23,874
| +30% | +$42.5K |
|
|
BIOR
1300
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
| $159K | 0.02% |
5,750
-2,608
| -31% | -$88.4K |
|
Similar funds
NCL
DG
VNT
SS
GWANC
LCM
LCM
FDCP
GSA Capital Partners's Q1 2023 Portfolio in Review
As of Q1 2023, GSA Capital Partners held 2,085 positions worth $1.01B, up 25% from $806M the previous quarter. Its ten largest holdings account for 4.2% of the portfolio.
GSA Capital Partners deployed $234M of net new capital in Q1 2023, opening 689 new positions and adding to 399 existing holdings. Its largest new stake was National Vision: 167,499 shares worth $3.16M.
By sector, the portfolio is most concentrated in Technology at 16% of assets, up from 14% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was Transocean, an estimated $2.59M trimmed.
- GSA Capital Partners's largest Q1 2023 buy was National Vision: 167,499 shares worth $3.16M.
- GSA Capital Partners added most to Altimmune in Q1 2023, an estimated $4.45M increase.
- GSA Capital Partners's biggest Q1 2023 reduction was Transocean, cutting an estimated $2.59M.
- GSA Capital Partners fully exited PG&E in Q1 2023, selling an estimated $7.74M.
- GSA Capital Partners's ten largest holdings make up 4.2% of its $1.01B portfolio in Q1 2023.
- GSA Capital Partners opened 689 new positions and closed 654 in Q1 2023.
- GSA Capital Partners's portfolio value rose 25% quarter-over-quarter to $1.01B.
Based on GSA Capital Partners's 13F filing for Q1 2023, filed 12 May 2023.